RG 6024

Drug Profile

RG 6024

Alternative Names: Anti-Influenza B monoclonal antibody - Genentech; MHAB 5553A; RG6024

Latest Information Update: 29 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genentech
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Influenza B virus infections

Most Recent Events

  • 01 Jan 2016 Genentech completes a phase I trial in Influenza-B virus infections (In volunteers) in Canada (IV) (NCT02528903)
  • 22 Oct 2015 Phase-I clinical trials in Influenza-B virus infections (In volunteers) in Canada (IV) (NCT02528903)
  • 24 Aug 2015 Genentech plans a phase I trial for Influenza B virus infections in Canada (NCT02528903)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top